Aon has invested in eMed Population Health, a provider of GLP-1 programs, to expand employer-sponsored access to GLP-1 therapies and scale obesity treatment solutions.
Aon’s investment follows the launch earlier this year of its subsidised GLP-1 weight management program for its U.S. workforce, developed by eMed, which in six months has enrolled more than 1,200 people.
Lisa Stevens, Chief Administrative Officer for Aon, commented, “As the leader of Aon’s People Organization, I know how important it’s been to include GLP-1 coverage as part of our own U.S. Total Rewards strategy.
“When you see the benefits it brings to people you work with every day, it really underscores how the decisions employers make today shape the future health and performance of our workforces and our businesses.”
-->
Stevens continued, “This strategic investment in eMed enables our firm to have an active role in offering a global solution that is focused on medication adherence that will be differentiated in the marketplace in helping employers reduce long-term health costs while improving the quality of life for their people.
“By aligning innovation with behaviour change and accountability, together we can deliver sustainable results at scale.”
Linda Yaccarino, CEO of eMed Population Health, said, “Today marks a game-changing partnership between Aon and eMed and is a win for both payers and participants.
“Our shared vision of market transformation is validated and accelerated by the investment from Aon. This strategic investment in eMed further enables our firm to play an active role in offering a differentiated global solution focused on medication adherence – helping employers reduce long-term health costs while improving quality of life for their people.”
Farheen Dam, Head of Health for North America at Aon, noted, “The rise of GLP-1 medications and its cost has sparked significant strategic considerations from employers looking to address obesity and other chronic conditions.
“We know that GLP-1s are not a one-size-fits-all strategy. This is why data, modelling and strategic guidance from our clinical, actuarial and pharmacy teams help employers build GLP-1s strategies that fit their population and objectives.”
About the Author
